文献速递前列腺癌男科与性医学

跨性别女性人群中的前列腺癌筛查与诊断

Prostate Cancer Screening and Diagnoses in the Transfeminine Population.
PubMed 文献 · Urology · 2024-11-21

本研究在医疗系统中纳入275112名有前列腺且年龄46岁以上的在世患者,其中315名为跨性别女性,按年龄、种族和区域剥夺指数1:5匹配顺性别对照。结果显示跨性别女性接受至少1次PSA检测的几率为顺性别的0.28倍(95%CI 0.20-0.38,P<.001),总PSA检测次数仅为顺性别的32%(95%CI 27%-37%,P<.001)。作者认为在最佳实践明确前跨性别女性应接受PSA检测,而当前显著较低的检测率可能代表医疗差异。

要点

  • 跨性别女性接受至少1次PSA检测的几率为顺性别对照的0.28倍(95%CI 0.20-0.38,P<.001)。
  • 跨性别女性总PSA检测次数仅为顺性别对照的32%(95%CI 27%-37%,P<.001)。
  • 作者认为在跨性别女性PSA检测最佳实践明确前,这些患者应接受PSA检测。

核心结论

  • 在跨性别女性PSA检测最佳实践明确前,这些患者应接受PSA检测;但结果显示其接受任何检测的可能性显著更低、终生检测次数显著更少,可能代表显著的医疗差异。

研究设计与样本

  • 研究纳入本医疗系统中有前列腺、目前年龄46岁及以上且在世的患者,跨性别女性通过诊断代码和病历审查确认。
  • 基于患者年龄、种族和区域剥夺指数创建1:5匹配队列,共纳入275112名患者,其中315名确认为跨性别女性。
  • 采用条件逻辑回归比较接受任何检测的比值,采用泊松回归比较总检测次数。

主要发现

  • 跨性别女性接受至少1次PSA检测的几率为顺性别患者的0.28倍(95%CI 0.20-0.38,P<.001)。
  • 跨性别女性总PSA检测次数仅为顺性别患者的32%(95%CI 27%-37%,P<.001)。

临床怎么用

  • 作者认为,在跨性别女性PSA检测最佳实践明确前,这些患者应接受PSA检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the frequency and rate at which transfeminine patients receive prostate-specific antigen testing compared to a matched cisgender cohort. METHODS: Patients with prostates who had encounters in our health system, are currently age 46 or older, and who are alive were included in our study. Transfeminine patients were identified through diagnosis codes and chart review. A 1:5 matched cohort was created based on patient age, race, and area deprivation index. Conditional logistic regression was done to compare odds of receiving any testing and Poisson regression was done to compare the total tests. RESULTS: A total of 275,112 patients were included in the study, of which 315 were confirmed to be transfeminine. A well-matched 1:5 propensity-matched cohort was created. Our results suggest that transfeminine patients were 0.28 (95% CI 0.20-0.38, P <.001) times as likely as cisgender patients to receive at least 1 PSA test at our institution and received only 32% (95% CI 27%-37%, P <.001) as many total PSA tests. CONCLUSION: Until more is known about the best practices for PSA testing in the transfeminine population, these patients should receive PSA testing. However, our results suggest that transfeminine patients are significantly less likely to receive any testing and significantly fewer tests in their lifetimes, which may represent a significant healthcare disparity.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Stephens A, Morrison C, Lutchka J, et al. Prostate Cancer Screening and Diagnoses in the Transfeminine Population. Urology. 2024. PMID: 39580118. doi:10.1016/j.urology.2024.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。